Erik Williams

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6793148/publications.pdf Version: 2024-02-01



FDIR WILLIAMS

#	Article	IF	CITATIONS
1	Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. Journal of the American Academy of Dermatology, 2021, 84, 1069-1071.	1.2	5
2	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Modern Pathology, 2021, 34, 252-263.	5.5	78
3	CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. Modern Pathology, 2021, 34, 358-370.	5.5	12
4	Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist, 2021, 26, e1263-e1272.	3.7	24
5	Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathologica, 2020, 140, 89-93.	7.7	32
6	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. Modern Pathology, 2020, 33, 2614-2625.	5.5	9
7	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. Modern Pathology, 2020, 33, 2397-2406.	5.5	16
8	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1–KMT2A–YAP1 and VIM–KMT2A fusions. Modern Pathology, 2020, 33, 2307-2317.	5.5	24
9	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. Modern Pathology, 2020, 33, 1466-1474.	5.5	28
10	Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Modern Pathology, 2019, 32, 844-854.	5.5	4
11	Factors associated with falseâ€negative pathologic diagnosis of calciphylaxis. Journal of Cutaneous Pathology, 2019, 46, 16-25.	1.3	20
12	Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations. Blood, 2019, 134, 2541-2541.	1.4	2
13	Metastatic medullary thyroid cancer to the brain: a case report and review of the literature. International Journal of Endocrine Oncology, 2018, 5, IJE11.	0.4	2
14	Malignant Melanoma Metastatic to Oligodendroglioma: Case Report and Literature Review of Tumor-to-Tumor Metastasis to Gliomas. Journal of Neuropathology and Experimental Neurology, 2018, 77, 549-554.	1.7	4
15	DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome. Acta Neuropathologica, 2018, 136, 779-792.	7.7	66
16	Case 31-2017. New England Journal of Medicine, 2017, 377, 1468-1477.	27.0	2
17	Intratumoral heterogeneity and <i>TERT</i> promoter mutations in progressive/higher-grade meningiomas. Oncotarget, 2017, 8, 109228-109237.	1.8	89
18	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. Journal of Neuropathology and Experimental Neurology, 2016, 75, 4-18.	1.7	81

#	Article	IF	CITATIONS
19	Srcasm Inhibits Fyn-Induced Cutaneous Carcinogenesis with Modulation of Notch1 and p53. Cancer Research, 2009, 69, 9439-9447.	0.9	50
20	Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus. Journal of Investigative Dermatology, 2009, 129, 2404-2410.	0.7	183